Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Madrigal Pharmaceuticals, Inc.
MDGL
NASDAQ·Healthcare·Biotechnology·Mkt cap $11.9B
$522.26
▲ +1.53%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$284.02 - $615.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 71.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Liver-directed selective mechanism of action minimizing systemic thyroid hormone effects
- Strategic partnership with Hoffmann-La Roche providing development and commercialization support
- Advanced clinical stage (Phase III) with lead candidate addressing large unmet NASH market need
- Focused pipeline strategy reducing development complexity and capital requirements
Bear Case
2 risks
- Low volatility (beta -1.1).
- Growth premium of 21.6x vs Biotech & Therapeutics peers. Significant premium - requires sustained high growth to justify.
Growth
Turning profitable
Phase III clinical trial success for resmetirom in NASH treatment
Value
Growth premium of 21.6x vs Biotech & Therapeutics peers. Significant premium - requires sustained high growth to justify.
Momentum
Weak
-5.9% over 3m
Quality
Excellent
High-growth business (257% revenue growth, 93% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying MDGL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 29, 2026
MAY 6, 2026
Reported EPS of -$3.25 vs -$3.61 consensus (+10.0% surprise). Revenue of $311.3M vs $301.1M expected (+3.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+10.0%
Next: Apr 29, 2026
Revenue trend · last 8Q
—
—
—
—
+1354%
+362%
+211%
+127%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$14.6M
$62.2M
$103.3M
$137.3M
$212.8M
$287.3M
$321.1M
$311.3M
Margins · last 8Q
Gross
—
Operating
—
Profit
-30.3%
Wall Street consensus
7 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
$649.00
▲ +24.3% vs $522.26
Latest: Piper Sandler · Jun 24, 2026
3 analysts covering